-+ 0.00%
-+ 0.00%
-+ 0.00%

Clearmind doses 2 more patients in CMND-100 alcohol use disorder trial cohort 4

PUBT·05/12/2026 12:41:19
Listen to the news
Clearmind doses 2 more patients in CMND-100 alcohol use disorder trial cohort 4
  • Clearmind Medicine dosed two more patients in fourth cohort of its FDA-cleared Phase I/IIa trial of CMND-100 for moderate to severe alcohol use disorder, lifting total treated to 20.
  • Results have not been presented; trial remains ongoing, with safety, tolerability, drug exposure, and early signs of benefit still being evaluated.
  • So far, study has shown encouraging safety and tolerability, with no serious adverse events reported in first three cohorts.
  • Fourth cohort moved to a higher dose following a positive independent safety review, supporting continued dose escalation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605120841PRIMZONEFULLFEED9718320) on May 12, 2026, and is solely responsible for the information contained therein.